Medicine
More
-
*Under new CEO, Sarepta focused on Duchenne muscular dystrophy drug. *Analysts expect company to relay FDA feedback in April. April 2- After three decades without bringing a drug to market, Sarepta Therapeutics Inc stands on the verge of a breakthrough with its treatment for a crippling genetic disorder that affects one in every 3,500 newborn boys.
-
NEW YORK-- Shares of Inovio Pharmaceuticals Inc. skidded Tuesday after the company reported negative data from a clinical trial of an experimental hepatitis C vaccine.
-
Bob and Suzanne Wright, co-founders of Autism Speaks, discuss the organization's efforts to foster research and raise awareness about Autism.
-
W. Scott Harrington's 7,000 patients have now been tested in Tulsa for hepatitis B and C as well as HIV, the virus that causes AIDS. Susan Rogers, the executive director of the Oklahoma Board of Dentistry, told The Associated Press that she talked with Tulsa County District Attorney Tim Harris on Monday to discuss whether Harrington is criminally liable.
-
Johnson & Johnson just won approval for a new diabetes drug, and the stock is at an all-time high today. Anthony Butler, Barclays, offers insight.
-
Enrollment season for Medicare Advantage plans and Obama's health reform plan is six months away. One big question is how many people will show up to be insured, reports CNBC's Bertha Coombs.
-
MUMBAI/ NEW DELHI, April 1- India's top court dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics.
-
Biotech has returned 20 percent for investors this year. Biogen IDEC CEO George Scangos, discusses the recent FDA approval of his company's drug, which is its first pill for multiple sclerosis.
-
Shares of Biogen Idec Inc. climbed in premarket trading Thursday, a day after federal regulators approved the drug developer's new multiple sclerosis treatment.
-
*Sales of Tecfidera expected to top $3 billion by 2017. WASHINGTON, March 27- U.S. regulators on Wednesday approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with annual sales topping $3 billion.
-
*Sales of Tecfidera expected to top $3 billion by 2017. WASHINGTON, March 27- U.S. regulators on Wednesday approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with annual sales topping $3 billion.
-
March 27- Biogen Idec Inc:. *Idec's Tecfidera (TM) approved in US as a first-line oral. *Source text for Eikon* Further company coverage ().
-
*Sales of Tecfidera expected to top $3 billion by 2017. March 27- U.S. regulators have approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with annual sales of more than $3 billion.
-
*Sales of Tecfidera expected to top $3 billion by 2017. March 27- U.S. regulators have approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with annual sales of more than $3 billion.
-
March 27- U.S. Food and Drug Administration:. *FDA says approved Biogen idec's tecfidera. capsules to treat adults with relapsing forms of Multiple Sclerosis.
-
March 27- U.S. regulators have approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with annual sales of more than $3 billion.
-
TRENTON, N.J.-- Shares of Trovagene Inc. jumped Wednesday after the maker of molecular disease-detecting tests launched its new urine-based test for a common, sexually transmitted virus that can cause cervical cancer, some other cancer types and genital warts.
-
A new study indicates that Obama's health care overhaul will result in a 32 percent claims cost increase which could translate into higher premiums for Americans.
-
NEW YORK, March 27- The logic behind weight-loss surgery seems simple: rearrange the digestive tract so the stomach can hold less food and the food bypasses part of the small intestine, allowing fewer of a meal's calories to be absorbed. A study of lab mice, published on Wednesday, begs to differ.
-
ANN ARBOR, Mich.-- Aastrom Biosciences Inc. is cutting its workforce by about 50 percent and ending a clinical drug trial. The Ann Arbor, Mich., company said that it will stop enrollment in and end the Phase 3 Revive clinical trial for patients with critical limb ischemia, or restricted blood supply.